Compare ANIP & CNXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANIP | CNXC |
|---|---|---|
| Founded | 2001 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 1999 | 2020 |
| Metric | ANIP | CNXC |
|---|---|---|
| Price | $80.50 | $27.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $110.00 | $54.80 |
| AVG Volume (30 Days) | 361.1K | ★ 1.3M |
| Earning Date | 05-08-2026 | 03-24-2026 |
| Dividend Yield | N/A | ★ 5.79% |
| EPS Growth | ★ 419.23 | N/A |
| EPS | ★ 1.28 | 0.33 |
| Revenue | $206,547,000.00 | ★ $9,825,771,000.00 |
| Revenue This Year | $21.01 | $5.29 |
| Revenue Next Year | $17.59 | $2.49 |
| P/E Ratio | ★ $61.88 | $86.58 |
| Revenue Growth | ★ 2.47 | 2.15 |
| 52 Week Low | $61.35 | $22.05 |
| 52 Week High | $99.50 | $62.14 |
| Indicator | ANIP | CNXC |
|---|---|---|
| Relative Strength Index (RSI) | 51.70 | 56.08 |
| Support Level | $79.69 | $24.93 |
| Resistance Level | $83.61 | $34.64 |
| Average True Range (ATR) | 2.43 | 1.48 |
| MACD | -0.35 | 0.44 |
| Stochastic Oscillator | 63.47 | 67.21 |
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
Concentrix Corp is a technology and services company. It designs, implements, and manages end-to-end solutions, including customer experience process optimization, technology development and design engineering, front- and back-office automation, analytics, and business transformation services. The company serves clients across multiple industry verticals, helping them manage customer engagement and operational processes throughout the customer lifecycle. The company operates in a single operating segment. It generates revenue through the provision of technology and services under contractual arrangements. Geographically, the company generates the maximum revenue from the Philippines and the rest from India, the United States, Great Britain, Germany, Canada and Other countries.